Huapont Life Sciences Co Ltd (002004) - Total Assets

Latest as of March 2026: CN¥29.83 Billion CNY ≈ $4.37 Billion USD

Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) holds total assets worth CN¥29.83 Billion CNY (≈ $4.37 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Huapont Life Sciences Co Ltd service its debt to assess how comfortably operating cash covers total debt obligations.

Huapont Life Sciences Co Ltd - Total Assets Trend (2001–2025)

This chart illustrates how Huapont Life Sciences Co Ltd's total assets have evolved over time, based on quarterly financial data. See what is Huapont Life Sciences Co Ltd's book value for net asset value and shareholders' equity analysis.

Huapont Life Sciences Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Huapont Life Sciences Co Ltd's total assets of CN¥29.83 Billion consist of 39.5% current assets and 60.5% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 9.9%
Accounts Receivable CN¥2.12 Billion 7.3%
Inventory CN¥2.02 Billion 6.9%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥1.61 Billion 5.5%
Goodwill CN¥1.98 Billion 6.8%

Asset Composition Trend (2001–2025)

This chart illustrates how Huapont Life Sciences Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002004 market cap overview.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Huapont Life Sciences Co Ltd's current assets represent 39.5% of total assets in 2025, a decrease from 64.8% in 2001.
  • Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 17.3% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2001.
  • Asset Diversification: The largest asset category is accounts receivable at 7.3% of total assets.

Huapont Life Sciences Co Ltd Competitors by Total Assets

Key competitors of Huapont Life Sciences Co Ltd based on total assets are shown below.

Company Country Total Assets
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
China CN¥58.40 Billion
Hunan Haili Chemical Co Ltd
SHG:600731
China CN¥4.46 Billion
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
China CN¥4.06 Billion
Insumos Agroquimicos SA
BA:INAG
Argentina AR$45.35 Billion
Nufarm Ltd
AU:NUF
Australia AU$4.80 Billion
Minbos Resources Ltd
AU:MNB
Australia AU$36.78 Million
Terragen Holdings Ltd
AU:TGH
Australia AU$5.84 Million
RLF Agtech Ltd
AU:RLF
Australia AU$24.62 Million

Huapont Life Sciences Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.40 1.14 0.98
Quick Ratio 1.18 0.92 0.78
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥3.53 Billion CN¥1.40 Billion CN¥-225.70 Million

Huapont Life Sciences Co Ltd - Advanced Valuation Insights

This section examines the relationship between Huapont Life Sciences Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.93
Latest Market Cap to Assets Ratio 0.05
Asset Growth Rate (YoY) -1.4%
Total Assets CN¥29.03 Billion
Market Capitalization $1.31 Billion USD

Valuation Analysis

Below Book Valuation: The market values Huapont Life Sciences Co Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Huapont Life Sciences Co Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Huapont Life Sciences Co Ltd (2001–2025)

The table below shows the annual total assets of Huapont Life Sciences Co Ltd from 2001 to 2025.

Year Total Assets Change
2025-12-31 CN¥29.03 Billion
≈ $4.25 Billion
-1.43%
2024-12-31 CN¥29.45 Billion
≈ $4.31 Billion
-4.16%
2023-12-31 CN¥30.73 Billion
≈ $4.50 Billion
+2.34%
2022-12-31 CN¥30.02 Billion
≈ $4.39 Billion
-0.07%
2021-12-31 CN¥30.04 Billion
≈ $4.40 Billion
+6.44%
2020-12-31 CN¥28.23 Billion
≈ $4.13 Billion
+5.97%
2019-12-31 CN¥26.64 Billion
≈ $3.90 Billion
+0.32%
2018-12-31 CN¥26.55 Billion
≈ $3.89 Billion
-8.73%
2017-12-31 CN¥29.09 Billion
≈ $4.26 Billion
+20.07%
2016-12-31 CN¥24.23 Billion
≈ $3.55 Billion
+22.92%
2015-12-31 CN¥19.71 Billion
≈ $2.88 Billion
+45.27%
2014-12-31 CN¥13.57 Billion
≈ $1.99 Billion
+77.42%
2013-12-31 CN¥7.65 Billion
≈ $1.12 Billion
+29.13%
2012-12-31 CN¥5.92 Billion
≈ $866.61 Million
+41.36%
2011-12-31 CN¥4.19 Billion
≈ $613.04 Million
+208.42%
2010-12-31 CN¥1.36 Billion
≈ $198.77 Million
+18.84%
2009-12-31 CN¥1.14 Billion
≈ $167.26 Million
+0.32%
2008-12-31 CN¥1.14 Billion
≈ $166.72 Million
+4.66%
2007-12-31 CN¥1.09 Billion
≈ $159.30 Million
+42.29%
2006-12-31 CN¥765.08 Million
≈ $111.96 Million
+60.11%
2005-12-31 CN¥477.85 Million
≈ $69.92 Million
-0.66%
2004-12-31 CN¥481.04 Million
≈ $70.39 Million
+113.10%
2003-12-31 CN¥225.73 Million
≈ $33.03 Million
+9.00%
2002-12-31 CN¥207.09 Million
≈ $30.30 Million
+55.23%
2001-12-31 CN¥133.41 Million
≈ $19.52 Million
--

About Huapont Life Sciences Co Ltd

SHE:002004 China Agricultural Inputs
Market Cap
$1.31 Billion
CN¥8.95 Billion CNY
Market Cap Rank
#7656 Global
#1676 in China
Share Price
CN¥4.52
Change (1 day)
+2.03%
52-Week Range
CN¥3.93 - CN¥5.88
All Time High
CN¥11.08
About

Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. The company is involved in the production and sale of pharmaceutical preparations and raw materials. It also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more